Research Analysts Set Expectations for Surmodics Q3 Earnings

Surmodics, Inc. (NASDAQ:SRDX) – Research analysts at Zacks Research decreased their Q3 2025 earnings per share estimates for shares of Surmodics in a report issued on Wednesday, February 19th. Zacks Research analyst D. Dey now forecasts that the company will post earnings per share of $0.08 for the quarter, down from their previous forecast of $0.09. The consensus estimate for Surmodics’ current full-year earnings is $0.20 per share. Zacks Research also issued estimates for Surmodics’ Q4 2025 earnings at $0.18 EPS, FY2025 earnings at $0.18 EPS, Q1 2026 earnings at $0.21 EPS, Q2 2026 earnings at $0.22 EPS and Q3 2026 earnings at $0.17 EPS.

Surmodics (NASDAQ:SRDX) last announced its quarterly earnings data on Thursday, February 6th. The company reported ($0.04) earnings per share for the quarter, topping the consensus estimate of ($0.08) by $0.04. Surmodics had a negative return on equity of 4.39% and a negative net margin of 11.48%.

SRDX has been the subject of a number of other research reports. StockNews.com assumed coverage on Surmodics in a research report on Monday, February 3rd. They set a “hold” rating for the company. Needham & Company LLC reissued a “hold” rating on shares of Surmodics in a research note on Thursday, January 30th. Five analysts have rated the stock with a hold rating, Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $50.00.

Surmodics Stock Performance

Shares of SRDX opened at $34.85 on Friday. The company has a market cap of $498.36 million, a PE ratio of -34.50 and a beta of 1.20. The company has a current ratio of 5.45, a quick ratio of 4.29 and a debt-to-equity ratio of 0.26. The stock has a 50-day moving average price of $37.02 and a 200-day moving average price of $38.36. Surmodics has a 12-month low of $25.17 and a 12-month high of $42.44.

Insider Buying and Selling at Surmodics

In other Surmodics news, CFO Timothy J. Arens sold 7,009 shares of the firm’s stock in a transaction that occurred on Tuesday, November 26th. The stock was sold at an average price of $39.44, for a total transaction of $276,434.96. Following the completion of the transaction, the chief financial officer now owns 70,350 shares in the company, valued at $2,774,604. This trade represents a 9.06 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. 8.90% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Surmodics

Several institutional investors have recently modified their holdings of the stock. Millennium Management LLC increased its holdings in Surmodics by 0.4% during the 4th quarter. Millennium Management LLC now owns 120,344 shares of the company’s stock worth $4,766,000 after purchasing an additional 509 shares during the period. Rhumbline Advisers increased its holdings in shares of Surmodics by 4.4% in the 4th quarter. Rhumbline Advisers now owns 20,250 shares of the company’s stock valued at $802,000 after acquiring an additional 861 shares during the period. Legal & General Group Plc grew its stake in Surmodics by 34.2% during the 4th quarter. Legal & General Group Plc now owns 3,452 shares of the company’s stock worth $137,000 after buying an additional 880 shares during the last quarter. Modus Advisors LLC acquired a new stake in Surmodics during the 4th quarter worth about $40,000. Finally, Quest Partners LLC lifted its position in Surmodics by 107,100.0% during the 3rd quarter. Quest Partners LLC now owns 1,072 shares of the company’s stock worth $42,000 after acquiring an additional 1,071 shares during the period. 96.63% of the stock is owned by institutional investors.

About Surmodics

Surmodics, Inc, together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD).